# Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy

> **NCT07306286** · PHASE2 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Pancreatic Adenocarcinoma Locally Advanced

## Interventions

- **RADIATION:** Cryoablation
- **DRUG:** Dual-Function Antibody PD-1/CTLA-4

## Key facts

- **NCT ID:** NCT07306286
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-15
- **Primary completion:** 2027-08-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07306286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07306286, "Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07306286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*